Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094546 | 0.93 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3088533 | 0.91 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3077056 | 0.89 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3094490 | 0.86 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3075658 | 0.85 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL4233737 | 0.84 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3094242 | 0.84 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3094247 | 0.84 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3077012 | 0.84 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3087120 | 0.83 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109612-B1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | claimed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | claimed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | claimed |
| EP-2109612-B1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008093075-A2 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | HSP90AA1, HSP90AB1, HSP90AB2P | HSP90AA1 1/4885HSP90AB1 2/4885TRAP1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.